WELIREG

This brand name is authorized in United States. It is also authorized in Canada, France, Israel, Lithuania, UK.

Active ingredients

The drug WELIREG contains one active pharmaceutical ingredient (API):

1	Belzutifan UNII 7K28NB895L - BELZUTIFAN
	Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan blocks the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes. In vivo, belzutifan demonstrated anti-tumor activity in mouse xenograft models of renal cell carcinoma.
	Read more about Belzutifan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WELIREG Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
WELIREG Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX74		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX74

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02528908
FR	Base de données publique des médicaments	63869763
IL	מִשְׂרַד הַבְּרִיאוּת	9270
LT	Valstybinė vaistų kontrolės tarnyba	1102750, 1102751
US	FDA, National Drug Code	0006-5331